|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||120.63 - 120.63|
|52 Week Range||96.00 - 120.90|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||23.28|
|Forward Dividend & Yield||1.40 (1.16%)|
|1y Target Est||N/A|
German science and technology company Merck KGaA raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials in October. Merck said 2019 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, would come in between 4.23 billion euros and 4.43 billion euros ($4.7-$4.9 billion), up from a previous prediction of between 4.15 billion euros and 4.35 billion euros. Shares in Merck were down 1.55% at 0828 GMT.
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
Merck KGaA and Pfizer said Friday that a late-stage clinical trial testing Bavencio as a first-line maintenance treatment for patients with certain forms of gastric cancer failed to meet the study's primary endpoints for survival. The current standard of care is chemotherapy. The German drugmaker and Pfizer formed an alliance in 2014 to develop and commercialize Bavencio, which was first approved by the U.S. Food and Drug Administration in 2017 as a treatment for metastatic Merkel cell carcinoma. Shares of Pfizer have fallen 15.44% year-to-date, while the S&P 500 is up about 23% for the year.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of MERCK...
Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer's Xalkori drug was given the designation https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0 last year.
Merck KGaA ("Merck") announced that its transaction with Versum Materials, Inc ("Versum") had been approved at a special meeting among Versum's shareholders. Merck had signed a definitive agreement to acquire Versum for a consideration of $53 in cash in April this year, notes Moody's.
FRANKFURT (Reuters) - Germany's Merck KGaA, which is taking over U.S. electronic chemicals maker Versum Materials, said it expected a slight tailwind from foreign exchange effects supporting earnings growth ...
European shares slid on Tuesday, with most sectors falling after the United States threatened to slap tariffs on goods from the European Union, with worries compounded by the IMF cutting its global growth forecast. The U.S. Trade Representative proposed a list of European Union products late on Monday on which to slap tariffs in retaliation to more than $11 billion of EU subsidies to Airbus the World Trade Organization has found cause "adverse effects" to the United States.
The business combination received unanimous approval from the boards of the German pharmaceutical company and Versum, Merck said in a Friday press release. Versum is a supplier of process chemicals, gases and semiconductor manufacturing equipment.
Germany's Merck KGaA sealed a $6.5 billion (4.9 billion pounds) takeover deal with Versum Materials after overturning a deal it had agreed with rival bidder Entegris. A bet on a recovery in electronic materials markets for semiconductor makers, the transaction will boost the share of profit that diversified Merck derives from high-tech chemicals to 27 percent from 19 percent previously. Merck, also maker of pharmaceuticals and biotech production gear, this week won the backing of Versum's board for its $53-per-share offer, lifted from $48 previously, having been spurned for weeks.
Versum Materials, Inc . (NYSE: VSM ) announced Monday that it received a revised proposal from Merck KGaA to acquire Versum for $53 per share, up from Merck's prior $48-per-share proposal on Feb. 27. ...
Merck KGaA won the backing of Versum's board for a sweetened $6.5 billion takeover proposal, overturning an agreed merger with rival Entegris as it bets on a recovery in electronic materials markets. "This proposal constitutes a 'Superior Proposal' as defined in Versum's previously announced merger agreement with Entegris, Inc.," Versum said in a statement on Monday. On a per share basis, Germany's Merck offered $53, up from $48 previously, after reviewing business data and following meetings between Merck Chief Executive Stefan Oschmann and Versum Chairman Seifi Ghasemi, filings showed.
Versum Materials Inc said on Monday that Merck KGaA had raised its offer for the company to $53 per share from $48. Merck had launched a hostile $5.9 billion all-cash takeover offer for Versum last month ...
Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.
Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.
"Merck’s proposal could reasonably be expected to result in a superior proposal," Versum, a maker of chemicals for the semiconductor industry, cited its board as saying in a statement on Friday. The board "has authorized Versum's management and its advisers to engage in further discussions with, and provide non-public information to, Merck," the statement added.